Related Experiment Video
Updated: Jul 2, 2025

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
267
Practice Consolidation Among US Medical Oncologists, 2015-2022.
Michael Milligan1,2,3, Parsa Erfani4, E John Orav4,5
1Harvard Radiation Oncology Program, Boston, MA.
JCO Oncology Practice
|February 26, 2024
Summary
Medical oncology practices consolidated significantly between 2015-2022, with fewer, larger practices emerging. Despite this trend, the geographic distribution of medical oncologists (MOs) remained stable, with implications for cancer care access and cost.
Area of Science:
- Health Services Research
- Oncology Practice Management
- Healthcare Economics
Background:
- Healthcare consolidation impacts cancer care delivery.
- Oncology practices have undergone significant consolidation over the past two decades.
- Understanding these trends is crucial for maintaining quality cancer care.
Purpose of the Study:
- To investigate practice consolidation trends among medical oncologists (MOs).
- To identify factors associated with MO practice consolidation.
- To analyze changes in the geographic distribution of MOs.
Main Methods:
- Utilized Medicare data from 2015-2022.
- Assessed MO practice consolidation using the Herfindahl-Hirschman Index (HHI) in hospital referral regions (HRRs).
- Examined MO distribution across counties using the Gini coefficient and employed multivariable linear regression to identify associated factors.
Main Results:
- The number of MOs increased 14.5%, while practices decreased 18.0%, leading to larger average practice sizes (4.26 to 5.95 MOs/practice).
- Median HHI increased by 9%, indicating greater MO practice consolidation.
- Higher baseline hospital consolidation and more hospital beds per capita correlated with MO practice consolidation; county-level MO distribution remained stable.
Conclusions:
- Medical oncology practices were highly concentrated in 2015 and further consolidated by 2022.
- While MOs' geographic distribution at the county level was stable, the effects of consolidation on cancer care cost, quality, and access require further investigation.
- Findings have significant implications for policymakers and payers in designing programs for high-quality, affordable cancer care.
Related Concept Videos
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

